Ann: Appendix 4C - June 2017 Quarterly Report, page-6

Good post...

Biotechs traditionally long paths to commercialisation routes with drug testing phases to FDA approval etc because of risks (to humans taking drugs) taking many many years. Promarker is predictive test and hence point of difference....as all really needs to prove is valid and reliable test which latest expanded study has proved. Risks to individuals undertaking test is of course ZERO, so all about whether reliable predictor.

This is probably where my grey area comes in as biotechs not my key area of expertise but from trader / investor now had expanded study to validate that best predictive test on the market for what it does. So why should commercialisation be slow from here is what I probably don't understand.....or at least enough.